Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
about
P1343
Synthesis of site-specific antibody-drug conjugates using unnatural amino acidsClinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancerThe role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerNational consensus in China on diagnosis and treatment of patients with advanced breast cancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewStrategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer TherapeuticsProgress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery SystemsAntibody-drug conjugates as novel anti-cancer chemotherapeuticsSite-specific functionalization of proteins and their applications to therapeutic antibodiesRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerImplications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugatesProfiling and targeting HER2-positive breast cancer using trastuzumab emtansineThe development of immunoconjugates for targeted cancer therapyAntibody Drug Conjugates: Preclinical ConsiderationsHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerGastric Cancer: New Drugs - New StrategiesStructural basis for high-affinity HER2 receptor binding by an engineered proteinMicrotubule-binding agents: a dynamic field of cancer therapeutics.Trastuzumab emtansine for HER2-positive advanced breast cancer.Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerTreatment of early-stage HER2+ breast cancer-an evolving fieldRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesChallenges and advances in the assessment of the disposition of antibody-drug conjugatesAntibody drug-conjugates targeting the tumor vasculature: Current and future developmentsIn vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugatesAntibody drug conjugates: design and selection of linker, payload and conjugation chemistrySortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo PotencyCaveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic CancerStructural Basis of Microtubule Destabilization by Potent Auristatin Anti-MitoticsMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionDexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Evolving Therapies and FAK Inhibitors for the Treatment of CancerCancer immunotherapy comes of ageSurface modified multifunctional nanomedicines for simultaneous imaging and therapy of cancer.Strategies for modern biomarker and drug development in oncology.A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer.The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.
P2860
Q24624489-6CF579E5-0E26-4638-A4FC-2C4F133998D5Q24632855-C3ED1453-104D-4E17-8FD6-6A57AD3398CAQ24656159-1FB2F710-4722-473B-B44F-FF32FF2A7F3BQ26775621-ACAD48CB-F6C6-4610-869F-0141DA76918AQ26777681-32C6E131-0CD2-4551-A02C-6CA02B8B31E5Q26777733-F62C46B7-ABE0-4DD5-BB4D-D759B44171A0Q26780335-C30436C7-CF04-47D9-92E8-A78C7435F2FEQ26782485-2E90363E-3C74-40E3-A4F0-F27F63B4DABBQ26800175-24022DDA-7171-4D67-8E94-66828FC1D9CFQ26830699-CED0EE93-277B-4112-9557-6E06C521AB1DQ27003258-1F1FDE01-25E1-4C97-B6FE-1DB37C3DC749Q27007486-276595D9-167A-47DC-A385-8B9ADB397853Q27015048-562262A7-910A-4412-888A-687CFE327D37Q27021990-86E7314B-5EE4-4E18-979A-8D018853D19CQ27022321-21241DF8-382F-4C65-A4D0-4F6699AD384DQ27025863-93813AA5-C166-4A1F-9354-8CC1D1BB31EFQ27028079-B0B4578F-D350-40E6-AA3B-C16EF1265527Q27664013-E2C9C593-9A09-4B0C-A016-3EA54A192EF9Q27690249-8AB2B4B5-537D-4C28-9AA3-25125449AF6FQ27851917-FAB044C3-A918-4884-88B3-3541CACFF2E0Q27853015-F2C95E03-D260-4F48-90AF-7B2F50D75720Q28072513-7AF5D9E9-D25B-4882-A88E-7451301254BFQ28081124-6D1C5DF0-5937-47C0-AC35-DBAD160E826CQ28083123-9B291CA4-8C79-425B-AC7A-2909E0E15849Q28085074-4B3717DF-FE41-4422-A04D-4A605F5925FCQ28270261-0FF4E673-9BD4-4BFC-909D-F6CD2C26268CQ28538658-A72575EB-A9A8-473E-9420-B7A975E9C538Q28544658-92F5BDF9-7967-424B-AD9C-736BEC5D570BQ28546010-79C4CABA-0D1A-4E75-9F48-D83625C9D990Q28546477-5C8FFB6B-6FC1-40B4-803F-978766C3F037Q28552050-EE3ADEA3-08A6-466A-ADF1-CF2DDE5EFC35Q28553497-2F46C088-5FCC-4122-8214-0BA7C1FD0514Q28829301-57E82F97-887A-4341-A937-8F4E689600F3Q28829762-161743DC-1656-421B-880A-49066FF4BF9FQ28972291-07619581-097F-486D-B8C3-A01AE442AE8EQ29619918-9B1672C0-54DF-4072-8203-6444102FA8C0Q30439353-AD1428E5-B0B2-46E7-87F3-78587D9626A2Q30590270-A5EEE1D1-47FA-48C5-BC13-D2A17FD4FF62Q33402778-2078006A-AD69-45DE-9EC0-9B85A48C4FB6Q33409083-0A97F0AD-9156-4682-8EFB-9F47E2949DA4
P2860
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@ast
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@en
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@nl
type
label
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@ast
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@en
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@nl
prefLabel
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@ast
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@en
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@nl
P2093
P921
P1433
P1476
Targeting HER2-positive breast ...... body-cytotoxic drug conjugate.
@en
P2093
Debra L Dugger
Elaine Mai
Frederic S Jacobson
Gail D Lewis Phillips
Guangmin Li
Hartmut Koeppen
John M Lambert
Kathryn L Parsons
Lisa M Crocker
Mark X Sliwkowski
P304
P356
10.1158/0008-5472.CAN-08-1776
P407
P4510
P577
2008-11-01T00:00:00Z